Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ACTINIUM PHARMACEUTICALS, INC.

(ATNM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
12/01/2021 12/02/2021 12/03/2021 12/06/2021 12/07/2021 Date
6.86(c) 6.8(c) 6.35(c) 6.53(c) 7.05 Last
90 090 149 820 237 389 110 405 85 856 Volume
-4.32% -0.87% -6.62% +2.83% +7.96% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1,26 M - -
Net income 2021 -23,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,73x
Yield 2021 -
Sales 2022 15,4 M - -
Net income 2022 -17,1 M - -
Net Debt 2022 - - -
P/E ratio 2022 -9,42x
Yield 2022 -
Capitalization 155 M 155 M -
Capi. / Sales 2021 123x
Capi. / Sales 2022 10,1x
Nbr of Employees 32
Free-Float 98,6%
More Financials
Company
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on Antibody Radiation-Conjugates (ARCs), which combine the targeting ability of antibodies with the cell-killing ability of radiation. Its clinical programs are focused on two primary areas: targeted conditioning prior to bone marrow transplant, adoptive cell or gene therapies and therapeutics, in combination with... 
Sector
Biotechnology & Medical Research
Calendar
12/11 | 05:30pmPresentation
More about the company
Ratings of Actinium Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about ACTINIUM PHARMACEUTICALS, INC.
11/12ACTINIUM PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDI..
AQ
11/12Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine ..
CI
11/12Actinium Highlights Actimab-A Combined with CD47 Immunotherapy Results in Upregulation ..
CI
11/12SITC 2021 : Actimab-A with CD47 Immunotherapy in AML
PU
11/12SITC 2021 : HER2 Targeted Radiotherapy with CD47 Immunotherapy in Solid Tumors
PU
11/09ACTINIUM PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Submission of ..
AQ
11/05Actinium Announces Multiple Abstracts Highlighting Iomab-B and Actimab-A Accepted for P..
AQ
11/05Actinium Announces Completion of Enrollment of Actimab-A CLAG-M Combination Trial in Pa..
AQ
11/04Actinium Announces Completion of Enrollment of Actimab-A CLAG-M Combination Trial in Pa..
CI
10/22NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
10/04ACTINIUM PHARMACEUTICALS : Announces Two Abstracts Highlighting Combinations of CD47 Targe..
AQ
09/29ACTINIUM PHARMACEUTICALS : to Present at the Cantor Fitzgerald Virtual Global Healthcare C..
AQ
09/29ACTINIUM PHARMACEUTICALS RALLY TAKES : Atnm)
AQ
09/28ACTINIUM PHARMACEUTICALS : Announces Expansion of R&D Team and Facilities to Accelerate Re..
AQ
09/28GENPREX : Appoints Mark Berger Chief Medical Officer
MT
More news
News in other languages on ACTINIUM PHARMACEUTICALS, INC.
09/15Actinium Pharmaceuticals achève le recrutement dans le cadre de l'essai de phase 3 de I..
06/17Actinium Pharmaceuticals obtient des brevets en Europe et au Japon pour un conjugué ant..
03/25Actinium Pharmaceuticals achève le recrutement de la deuxième cohorte de doses de l'ess..
03/24Actinium Pharmaceuticals commence à recruter des patients dans le cadre de l'étude Ioma..
03/03Actinium Pharmaceuticals nomme Mark Kubik au poste de directeur commercial.
More news
Analyst Recommendations on ACTINIUM PHARMACEUTICALS, INC.
More recommendations
Chart ACTINIUM PHARMACEUTICALS, INC.
Duration : Period :
Actinium Pharmaceuticals, Inc. Technical Analysis Chart | ATNM | US00507W2061 | MarketScreener
Technical analysis trends ACTINIUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 6,53 $
Average target price 30,00 $
Spread / Average Target 359%
EPS Revisions
Managers and Directors
Sandesh Seth Chairman & Chief Executive Officer
Steve O'Loughlin Chief Financial Officer
Avinash Desai Chief Medical Officer
Mary Mei Chen Vice President-Clinical Development
Monideepa Roy VP-Corporate Development, Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ACTINIUM PHARMACEUTICALS, INC.-18.59%144
GILEAD SCIENCES, INC.19.29%87 180
BIONTECH SE310.30%67 585
REGENERON PHARMACEUTICALS29.37%65 347
WUXI APPTEC CO., LTD.21.75%63 017
VERTEX PHARMACEUTICALS-13.24%52 137